| Literature DB >> 25006123 |
Alex Yick-Lun So1, Reeshelle Sookram1, Aadel A Chaudhuri2, Aarathi Minisandram1, David Cheng1, Catherine Xie1, Ee Lyn Lim1, Yvette Garcia Flores1, Shuai Jiang1, Jocelyn Tammy Kim1, Christopher Keown3, Parameswaran Ramakrishnan4, David Baltimore1.
Abstract
The oncomir microRNA-125b (miR-125b) is upregulated in a variety of human neoplastic blood disorders and constitutive upregulation of miR-125b in mice can promote myeloid and B-cell leukemia. We found that miR-125b promotes myeloid and B-cell neoplasm by inducing tumorigenesis in hematopoietic progenitor cells. Our study demonstrates that miR-125b induces myeloid leukemia by enhancing myeloid progenitor output from stem cells as well as inducing immortality, self-renewal, and tumorigenesis in myeloid progenitors. Through functional and genetic analyses, we demonstrated that miR-125b induces myeloid and B-cell leukemia by inhibiting interferon regulatory factor 4 (IRF4) but through distinct mechanisms; it induces myeloid leukemia through repressing IRF4 at the messenger RNA (mRNA) level without altering the genomic DNA and induces B-cell leukemia via genetic deletion of the gene encoding IRF4.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25006123 PMCID: PMC4148772 DOI: 10.1182/blood-2014-02-553842
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113